# Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo

> **NCT06577090** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Skye Bioscience, Inc.** · enrollment: 136 (actual)

## Conditions studied

- Obesity

## Interventions

- **BIOLOGICAL:** Nimacimab injection
- **BIOLOGICAL:** Nimacimab placebo injection
- **COMBINATION_PRODUCT:** semaglutide injection
- **BIOLOGICAL:** Nimacimab 300 mg injection

## Key facts

- **NCT ID:** NCT06577090
- **Lead sponsor:** Skye Bioscience, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-08-22
- **Primary completion:** 2026-11-20
- **Final completion:** 2027-02-28
- **Target enrollment:** 136 (ACTUAL)
- **Last updated:** 2026-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06577090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06577090, "Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06577090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*